Sherpa Healthcare Partners Appoints Veteran MedTech Executive Raymond W. Cohen as Venture Partner
Sherpa Healthcare Partners has appointed Raymond W. Cohen as Venture Partner. Cohen, a veteran healthcare executive, recently served as CEO and board member of Axonics, a medical technology company he co-founded in 2013 and took public in 2018. Under his leadership, Axonics achieved notable recognition, ranking first in both the 2021 Deloitte Technology Fast 500™ and 2022 Financial Times fastest-growing companies in the Americas list.
Cohen retired as CEO following Boston Scientific 's (NYSE: BSX) $3.7 billion acquisition of Axonics in November 2024. Before Axonics, he was CEO of Vessix Vascular, which was also acquired by Boston Scientific in 2012. The appointment aims to leverage Cohen's extensive experience in growing MedTech companies to support Sherpa's investment activities in innovative healthcare technologies.
Sherpa Healthcare Partners ha nominato Raymond W. Cohen come Partner di Venture. Cohen, un esperto dirigente nel settore sanitario, ha recentemente ricoperto il ruolo di CEO e membro del consiglio di amministrazione di Axonics, un'azienda di tecnologia medica che ha co-fondato nel 2013 e quotato in borsa nel 2018. Sotto la sua guida, Axonics ha ottenuto un riconoscimento notevole, piazzandosi al primo posto sia nella lista 2021 Deloitte Technology Fast 500™ che in quella delle aziende a più rapida crescita delle Americhe del Financial Times nel 2022.
Cohen si è ritirato come CEO dopo l'acquisizione da parte di Boston Scientific (NYSE: BSX) di Axonics per 3,7 miliardi di dollari avvenuta a novembre 2024. Prima di Axonics, è stato CEO di Vessix Vascular, anch'essa acquisita da Boston Scientific nel 2012. La nomina mira a sfruttare l'ampia esperienza di Cohen nella crescita delle aziende MedTech per supportare le attività di investimento di Sherpa nelle tecnologie sanitarie innovative.
Sherpa Healthcare Partners ha nombrado a Raymond W. Cohen como Socio de Riesgo. Cohen, un veterano ejecutivo del sector salud, recientemente se desempeñó como CEO y miembro de la junta de Axonics, una empresa de tecnología médica que cofundó en 2013 y que salió a bolsa en 2018. Bajo su liderazgo, Axonics obtuvo un notable reconocimiento, ocupando el primer lugar tanto en la lista 2021 Deloitte Technology Fast 500™ como en la lista de empresas de más rápido crecimiento en las Américas de Financial Times en 2022.
Cohen se retiró como CEO tras la adquisición de Boston Scientific (NYSE: BSX) de Axonics por 3.7 mil millones de dólares en noviembre de 2024. Antes de Axonics, fue CEO de Vessix Vascular, que también fue adquirida por Boston Scientific en 2012. La nominación tiene como objetivo aprovechar la amplia experiencia de Cohen en el crecimiento de empresas MedTech para apoyar las actividades de inversión de Sherpa en tecnologías de salud innovadoras.
Sherpa Healthcare Partners는 Raymond W. Cohen을 벤처 파트너로 임명했습니다. Cohen은 베테랑 의료 경영자로, 최근 2013년에 공동 설립하고 2018년에 상장한 의료 기술 회사인 Axonics의 CEO 및 이사회를 지냈습니다. 그의 리더십 아래, Axonics는 2021년 Deloitte Technology Fast 500™ 및 2022년 Financial Times에서 가장 빠르게 성장하는 아메리카 기업 목록에서 1위를 차지하며 주목받았습니다.
Cohen은 2024년 11월 Boston Scientific (NYSE: BSX)의 37억 달러 규모 Axonics 인수에 따라 CEO 직에서 은퇴했습니다. Axonics 이전에 그는 2012년에 Boston Scientific에 의해 인수된 Vessix Vascular의 CEO였습니다. 이번 임명은 Cohen의 폭넓은 MedTech 기업 성장 경험을 활용해 Sherpa의 혁신적인 의료 기술 투자 활동을 지원하기 위한 것입니다.
Sherpa Healthcare Partners a nommé Raymond W. Cohen en tant que Partenaire de Risque. Cohen, un vétéran de l'exécution dans le secteur de la santé, a récemment été PDG et membre du conseil d'administration de Axonics, une entreprise de technologie médicale qu'il a co-fondée en 2013 et entrée en bourse en 2018. Sous sa direction, Axonics a obtenu une reconnaissance notable, se classant au premier rang dans à la fois la liste 2021 Deloitte Technology Fast 500™ et la liste des entreprises à la croissance la plus rapide des Amériques selon le Financial Times en 2022.
Cohen a pris sa retraite en tant que PDG après l'acquisition d'Axonics par Boston Scientific (NYSE: BSX) pour 3,7 milliards de dollars en novembre 2024. Avant Axonics, il était PDG de Vessix Vascular, qui a également été acquise par Boston Scientific en 2012. Cette nomination vise à tirer parti de l'expérience approfondie de Cohen dans la croissance des entreprises MedTech pour soutenir les activités d'investissement de Sherpa dans les technologies de santé innovantes.
Sherpa Healthcare Partners hat Raymond W. Cohen zum Venture Partner ernannt. Cohen, ein erfahrener Führungskraft im Gesundheitswesen, war kürzlich CEO und Vorstandsmitglied von Axonics, einem Medizintechnikunternehmen, das er 2013 mitbegründete und 2018 an die Börse brachte. Unter seiner Leitung erreichte Axonics bemerkenswerte Auszeichnungen und belegte den ersten Platz sowohl in der Liste 2021 Deloitte Technology Fast 500™ als auch in der Liste der am schnellsten wachsenden Unternehmen in den Amerikas von Financial Times im Jahr 2022.
Im November 2024 trat Cohen als CEO zurück, nachdem Boston Scientific (NYSE: BSX) Axonics für 3,7 Milliarden Dollar übernommen hatte. Zuvor war er CEO von Vessix Vascular, das 2012 ebenfalls von Boston Scientific übernommen wurde. Die Ernennung zielt darauf ab, Cohens umfangreiche Erfahrung im Wachstum von MedTech-Unternehmen zu nutzen, um die Investitionstätigkeiten von Sherpa im Bereich innovativer Gesundheitstechnologien zu unterstützen.
- Successful track record of Cohen in leading Axonics to a $3.7B acquisition by BSX
- Demonstrated expertise in MedTech sector with multiple successful exits
- Strong performance history with Axonics ranking #1 in prestigious growth rankings
- None.
Mr. Cohen is a seasoned healthcare executive and until recently, served as the CEO and member of the board of directors of Axonics, Inc., an
Axonics ranked No. 1 on the 2021 Deloitte Technology Fast 500™ and the 2022 Financial Times ranking of the fastest growing companies in the
"Having worked with Ray as one of the earliest investors of Axonics, we are enthusiastic to have him join the team," said Darren Cai, Managing Partner of Sherpa Healthcare Partners. "Since our inception, Sherpa has been committed to investing in innovative technologies and therapies that improve human health, and Ray's extensive experience and proven track record in growing MedTech companies will be highly accretive to our existing investment activities."
"I am excited to be joining Sherpa Healthcare Partners and look forward to working with talented entrepreneurs who are leaders in their respective fields," said Cohen. "I chose to work with Sherpa based on the integrity of the managing partners and their commitment to funding innovative therapies and devices."
About Raymond W. Cohen
Mr. Cohen has over 40 years of experience in the life sciences industry. He currently serves as the chairman of the board of SoniVie, Ltd, an Israeli-clinical stage company developing a catheter-based high frequency ultrasound renal denervation device treatment for hypertension. Cohen also serves as an independent director of Kestra Medical Technologies, Inc., a WA-based commercial stage company manufacturing and marketing a wearable defibrillator product for patients at temporary risk of life-threatening cardiac arrhythmias. Kestra filed an S-1 in December 2024 with a view towards an IPO on the NASDAQ.
During 2024, Mr. Cohen received the annual MedTech MVP Award for 2024 and was also named Businessperson of the Year by the Orange County Business Journal. In 2021, Mr. Cohen received a lifetime achievement award from SoCal Bio for his four decades of work in medical technology. In late 2020, Mr. Cohen was named as Entrepreneur of the Year by Ernst & Young for the Pacific Southwest United States.
About Sherpa Healthcare Partners
Sherpa Healthcare Partners invests in leading and innovative companies across the healthcare industry, including pharma, Genetech, MedTech, and medical services. Sherpa invests in companies with highly innovative technologies or extraordinary growth potential. For more information on Sherpa Healthcare Partners, please visit https://www.sherpahp.com
Sherpa contact:
Name: Xinran Wang
Email: wangxr@sherpahp.com
Raymond W. Cohen contact:
Email: rcohen@lifescience-advisors.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/sherpa-healthcare-partners-appoints-veteran-medtech-executive-raymond-w-cohen-as-venture-partner-302341525.html
SOURCE Sherpa Healthcare Partners
FAQ
How much did Boston Scientific (BSX) pay to acquire Axonics in 2024?
What were Raymond Cohen's major achievements at Axonics before the BSX acquisition?
What is Raymond Cohen's new role at Sherpa Healthcare Partners?
How many companies led by Raymond Cohen has BSX acquired?
